Papain-like lysosomal cysteine proteases are processive and digestive enzymes that are expressed in organisms from bacteria to humans. Increasing knowledge about the physiological and pathological roles of cysteine proteases is bringing them into the focus of drug discovery research. These proteases have rather short active-site clefts, comprising three well defined substratebinding subsites (S2, S1 and S1Ј) and additional broad binding areas (S4, S3, S2Ј and S3Ј). The geometry of the active site distinguishes cysteine proteases from other protease classes, such as serine and aspartic proteases, which have six and eight substrate-binding sites respectively. Exopeptidases (cathepsins B, C, H and X), in contrast with endopeptidases (such as cathepsins L, S, V and F), possess structural features that facilitate the binding of N-and C-terminal groups of substrates into the active-site cleft. Other than a clear preference for free chain termini in the case of exopeptidases, the substrate-binding sites exhibit no strict specificities. Instead, their subsite preferences arise more from the specific exclusion of substrate types. This presents a challenge for the design of inhibitors to target a specific cathepsin: only the cumulative effect of an assembly of inhibitor fragments will bring the desired result.
Introduction
The physiological roles of lysosomal cysteine proteases now emerging from research are bringing these proteases increasingly into focus as drug targets for a wide range of diseases, such as cancer, rheumatoid arthritis and osteoarthritis, multiple sclerosis and muscular dystrophy (reviewed in [1] ). For many diseases resulting from excess proteolysis, no inhibitors have yet been identified with the necessary profile for use as therapy. Thus research into the physiological roles of proteases and into the identification of substances able to modulate them will remain a priority of both science and the pharmaceutical industry for the foreseeable future. For now, drug design proceeds hand in hand with the discovery of biological roles for these enzymes. The inhibitor that unravels a specific role can immediately become a drug candidate.
It is estimated that there are around 500-600 proteases in the human genome, of which about 400 have already been identified [2] . In lysosomes there are around 60 hydrolases [3] , which include a group of about a dozen papain-like lysosomal cysteine proteases (papain-like cathepsins). Their relatively small size, their uniquely reactive cysteine thiol group (pK a between 2.5 and 3.5 [4] ) and their unique reactive mechanism make these enzymes attractive targets for drug design. There are 11 human enzymes currently known (cathepsins B, C, F, H, L, K, O, S, V, X and W) [1, 5] , and it is quite likely that the list has already been completed. Human gene databank searches have not indicated any new members of the family (B. Turk and A. Sali, unpublished work).
The use of biochemical techniques led to the discovery of the classical cathepsins (B, C, H, L and S), cathepsin C being the first [6] , whereas the other cathepsins (F, K, O, V, X and W) were discovered in the 1990s by means of DNA manipulation techniques. Only cathepsins O and W have not yet been characterized biochemically. The papain-like fold was revealed in the early days of crystallography [7] , whereas structural characterization of cathepsins began in the early 1990s with the cathepsin B structure [8] . Currently, crystal structures of all human representatives or their mammalian analogues, except for cathepsins O and W, have been determined and are available in the Protein Databank (PDB; Table 1 ). The relevance of cathepsins as potential drug targets is best indicated by the fact that four (cathepsins K, S, V and recently F) out of nine structures of cathepsins were published by industrial research groups. The structures of cathepsins L [9] and S [10] have also been reported by industrial groups (but not in the public domain). An additional publication describing complexes of 
Cathepsin physiology
Protein digestion in lysosomes was long believed to be the major physiological role of the papain-like lysosomal cysteine proteases [11] . Analyses of gene knockouts suggested that this function is not dependent on any single cathepsin [12] [13] [14] [15] [16] [17] . Moreover, analyses of gene knockouts and of locations of mutations on genes of lysosomal cysteine proteases responsible for some hereditary diseases revealed several specific biological functions. These functions are a result of limited proteolysis of their target substrates, and rely additionally on co-localization and timing. For example, cathepsin K has been found to be crucial in bone remodelling [12, 18] .
Cathepsin S is the major processing enzyme of the MHC class II-associated invariant chain, and is thus essential for the normal functioning of MHC class II-associated antigen processing and presentation [15, 16] . Cathepsins L and F have been shown to participate in the same process, primarily in tissues or cells not expressing cathepsin S [15, 19] , although the role of the former has probably been taken over by cathepsin V in humans [20] .
Cathepsin L-deficient mice developed periodic hair loss and epidermal hyperplasia, indicating that cathepsin L is involved in epidermal homoeostasis and regular hair follicle morphogenesis and cycling [17] . At 1 year old, cathepsin L-deficient mice [21] exhibited histomorphological and functional alterations of the heart, resulting in dilated cardiomyopathy, which is a frequent cause of heart failure.
Cells derived from cathepsin C-deficient mice failed to show activation of groups of serine proteases from granules of immune (cytotoxic T lymphocytes, natural killer cells) and inflammatory (neutrophils, mast cells) cells involved primarily in the defence of the organism, demonstrating that cathepsin C is involved in this activation [13, 22] . The current list of unprocessed zymogens of proteases in cathepsin C knockout mice includes granzymes A, B and C, cathepsin G, neutrophil elastase and chymase. More information about the processes in which the lysosomal papain-like cysteine proteases participate can be found elsewhere [1, 5, 11, 18, 23, 24] .
Cathepsin pathology
Lysosomal cysteine proteases have been found to be associated with a number of pathologies, including cancer, inflammation, rheumatoid arthritis and osteoarthritis, multiple sclerosis, muscular dystrophy, pancreatitis, liver disorders, lung disorders, lysosomal disorders, Batten's disease, diabetes and myocardial disorders. In many of these diseases, the lysosomal enzymes have been found in the extracellular and extralysosomal environment in their (zymogenic) 'pro' forms, which are substantially more stable than the mature enzymes (reviewed in [5, 11, 18, 23] ).
A few genetic disorders have been traced to the genes encoding lysosomal cysteine proteases. Pycnodysostosis, which is characterized by severe bone abnormalities, is associated with a loss-of-function mutation of cathepsin K [25] , while a loss-of-function mutation in the cathepsin C gene leads to Papillon-Lefevre syndrome, characterized in humans by palmoplantar keratosis and severe, early-onset periodontitis [26, 27] . It has been suggested that these effects are likely to be the result of incomplete processing of some as yet unidentified proteases presumably involved in establishing or maintaining the structural organization of the epidermis at the extremities and the integrity of tissues surrounding the teeth, as well as in the processing of proteins such as keratins [28] . In addition, cathepsin C may be involved in chronic airway diseases such as asthma [29] .
Interestingly, the down-regulation of natural inhibitors, as demonstrated by a mutation in the gene for stefin B, predisposes affected individuals to a hereditary form of myoclonal epilepsy [30, 31] .
Cathepsin structure
Papain-like lysosomal cysteine proteases share the common fold of a papain-like structure. Cathepsin L, as a typical endopeptidase, has been chosen as the representative of the family ( Figure 1) . A papain-like fold consists of two domains, reminiscent of a closed book with the spine to the front. The domains separate on the top in a 'V'-shaped active-site cleft, in the middle of which are found residues Cys 25 and His 159 , one from each domain, which form the catalytic site of the enzyme. The most prominent feature of the left (L-) domain is the central ␣-helix, which is approx. 30 residues long; the right (R-) domain forms a kind of a ␤-barrel, which includes a shorter ␣-helical motif. (The terms left and right domains refer to the standard view shown in Figure 1 .) The enzymes are monomeric proteins, with molecular masses between 22 and 25 and His 159 are shown as atom balls. The figure was prepared using the program Ribbons [74] . a molecular mass of 200 kDa [32] .
Cathepsin substrate-binding sites
The nomenclature of the assignment of sites of interaction between a polypeptide substrate and a protease originates from the work of Schechter and Berger [33] (Figure 2 ). They showed that the kinetics of substrate hydrolysis are influenced by polypeptide chain length up to seven amino acids, and concluded that there are seven substrate-binding sites on the papain molecule. Three decades later, when a sufficient number of protease-inhibitor structures had become available, the definition of Schechter and Berger of substrate-binding sites on the papain-like enzymes was revisited and redefined [34] . The inspection of structures revealed that the base and walls of the substrate-binding sites are formed by four chain segments comprising two shorter loops on the Ldomain (residues 19-25 and 61-69) and two longer loops on the R-domain (residues 136-162 and 182-213) (Figures 1 and 3b) . A third loop from the Ldomain might be involved as well if the disulphide Cys 22 -Cys 65 , which connects the two L-domain loops at the top, is considered an additional loop closure.
The superimposed structures of complexes of substrate-analogue inhibitors with cathepsins and papain-like enzymes were divided into five groups. Figures 4(a) and 4(c) show substrate-analogue inhibitors, presumably revealing the geometry of binding of substrate residues. Substrate residues bind along the active-site cleft in an extended conformation, with the side chains oriented alternately left and right -towards the L-and R-domains. Residues P2, P1 and P1Ј bind into well defined binding sites. Positioning of these residues is governed by interactions that involve both main-chain as well as side-chain atoms. The S2 binding site is actually the only deep binding pocket, whereas the S1 and S1Ј sites provide a binding surface. The positioning of the P3 residue is mediated only by side-chain interactions. For this reason, the binding geometries of the latter are scattered over a broad area and are unique for each substrate-protease pair. On the prime side of the binding cleft, the P2Ј residue binding site appears to be quite well defined. However, current knowledge is based on specific interactions between the inhibitor CA030 and the parts of cathepsin B structure responsible for its carboxydipeptidase activity (Figure 4c ) [35] . It is likely that interactions within the S2Ј site of an endopeptidase may be different. Modelling of the binding geometry of a substrate is based on information gained from crystal structures of substrate-analogue inhibitors and their interactions with a papain-like protease active site (see Figures 4a-4c) . Substrate residues are shown in stick representation and are denoted using the Schechter and Berger nomenclature [33] . Cathepsin L is shown in dark grey surface representation. The surface of the catalytic cysteine side chain is highlighted. The cathepsin L surface was generated with GRASP [77] . The Figure was prepared using MAIN [75] and rendered with Raster3D Main-chain interactions do not constrain the positioning of the substrate into binding sites beyond S3 and S2Ј. These substrate residues dock on the surfaces of the underlying enzymes in their own way (Figure 4a ). In particular, for the non-primed binding sites, the structures suggest that a common S4 binding site, and also an S3Ј site, do not exist. Therefore it was suggested that the substrate residue binding regions beyond S2 and S2Ј should not be called sites, but areas [34] . The papain-like proteases thus represent a special class of proteolytic enzymes with the smallest number of substrate-binding sites, as opposed to chymotrypsin-like serine proteases with six [36] and aspartic proteases with eight [37] binding sites.
Low-molecular-mass inhibitors
The presence of a rather small number of substrate-binding sites seems to facilitate covalent interactions with low-molecular-mass inhibitors. Covalent interactions, however, impose tight constraints on the geometry of binding. It is thus not surprising that natural low-molecular-mass inhibitors such as E64 [trans-epoxysuccinyl-L-leucylamido-(4-guanidino)butane] and leupeptin interact covalently with the reactive site and bind only into the non-primed binding side of the active-site cleft, whereas inhibitors that bind into both sides (primed as well as non-primed) have been designed only recently.
The first inhibitor constructs, the structures of which were determined in complex with papain, were based on the chloromethyl reactive group [38] . These studies revealed binding of substrate residues in the non-primed binding sites of the enzyme (Figure 4a ). Around the same time, a natural cysteine protease inhibitor, named E64, was discovered [39, 40] . E64 utilizes an epoxysuccinyl group to interact covalently with the reactive-site cysteine ( Figure 5 ). The structures of E64 [41] and its analogues [42] revealed that they bind into the non-primed region of the active site; however, they bind in the direction of propeptide binding, opposite to that of substrate binding (Figure 4b) .
Replacement of the terminal agmatine residue with proline was essential for the conversion of E64, a general inhibitor of papain-like cysteine proteases, into the cathepsin B-specific inhibitor CA030 ( Figure 6 ). The crystal structure of CA030 in complex with human cathepsin B [35] revealed the essence of the change. CA030 binds, in contrast with E64, into the primed binding side in the direction of substrate binding. Switching the sides of binding was made possible by specific interactions. The carboxylic group of the C-terminal residue of CA030 mimics the C-terminus of a substrate and docks against the occluding loop residues His 110 and His 111 (Figure 4c ; also see Figure 7) . Alignment of the binding geometries of E64 and CA030 ( Figure 6 ) [35] shows that the epoxysuccinyl group possesses internal symmetry with two carboxylic heads, mimicking a polypeptide C-terminus to which amino acid residues can be attached. The synthesis of double-head inhibitors such as NS134 and CLIK066 followed [43] [44] [45] (Figure 6 Inhibitor constructs using the vinyl sulphone reactive group (Figure 4d ) [47] [48] [49] , and exceptionally even a chloromethyl inhibitor with a long side chain of a P1-mimicking residue [50] (Figure 4a ), can reach into the S1Ј binding site. A series of compounds synthetized at GlaxoSmithKline revealed that the irreversible covalent interaction with the reactive-site cysteine is not mandatory (Figure 4e ). These compounds span both sides of the active-site cleft and block the reactive site with fragments that resemble the peptide bond, but which cannot be hydrolysed [51] . Additional information regarding inhibitors and their chemistry can be found elsewhere [24, 52, 53] .
Exopeptidases
The 'V'-shaped active-site cleft of endopeptidases (cathepsins F, L, K, O, S and V) extends along the whole length of the two-domain interface on both sides, whereas the exopeptidases (cathepsins B, C, H and X) possess additional features that block access to parts of the active-site cleft (Figure 7) . The role of these features is dual: they prevent binding of longer peptidyl substrates, and they dock with charged N-or C-termini of substrates by utilizing selective electrostatic interactions. The carboxydipeptidase cathepsin B [8] has an approx. 20-residue insertion, termed the occluding loop, that blocks the active-site cleft on the primed binding side beyond S2Ј. Its two histidine residues, His 110 and His 111 , are cruical for docking with the C-terminal carboxylic group of a substrate residue. Interestingly, cathepsin B also exhibits an endopeptidase activity that is made possible by the flexible occluding loop, which can occupy positions outside the active-site cleft [54] [55] [56] .
Cathepsin X is primarily a carboxymonopeptidase [57] that can also exhibit carboxydipeptidase activity [58] . The crystal structure showed that a histidine residue, His 23 , positioned within a short loop termed a mini-loop [57] , is the anchor for the carboxylic group of the substrate C-terminal residue [59] . In the free enzyme structure, the histidine ring occupies the position that in related cathepsins is the S2Ј substrate-binding site. A simple modelling study (manual rotation about the side-chain bonds) suggested that the histidine ring can adapt a position equivalent to His 110 of cathepsin B, thereby allowing the carboxydipeptidase mode. Cathepsin H is an amino-monopeptidase. The crystal structure of the pig enzyme [60] revealed the binding of an eight-residue segment of the propeptide, called the mini-chain. The mini-chain is covalently fastened to the body of the enzyme via a disulphide bond. It binds into the active-site cleft of the enzyme in the direction of a bound substrate. The negatively charged carboxylic group of its C-terminal residue, Thr 83P , attracts the positively charged N-terminus of a substrate and thereby facilitates the aminopeptidase activity of cathepsin H. Thr 83P actually mimics a substrate P2 residue by occupying the position that in related enzymes is the S2 binding site. The mini-chain is fastened additionally to the enzyme surface by a four-residue insertion (Lys 155A to Asp 155D ) and a carbohydrate chain attached to Asn 112 . Interestingly, the positioning of the cathepsin H mini-chain closely resembles the positioning of the C-terminus of a distant homologue, bleomycin hydrolase [61] .
Cathepsin C (also termed dipeptidyl peptidase I) is an amino-dipeptidase. Cathepsin C has four independent active sites located on the external surface of the tetrahedral molecule. The exposure of the active sites makes cathepsin C unique when compared with other oligomeric proteolytic enzymes. Thus the 20 S proteasome [62, 63] , bleomycin hydrolase [61] , tryptase [64] and tricorn protease [65] have their active sites on the inside surface. Proteasomes are barrel-like structures composed of four rings of ␣-and ␤-subunits, which cleave unfolded proteins captured in the central cavity into short peptides. Tryptases are flat tetramers with a central pore in which the active sites reside. The pore restricts the size of accessible substrates and inhibitors. The active sites of bleomycin hydrolase and tricorn protease are located similarly within the hexameric structure. Its exposed active sites enable cathepsin C to hydrolyse protein substrates in their native state, regardless of their size. Its design, supported by the oligomeric structure, confines the activity of cathepsin C to an amino-dipeptidase and thereby makes it suitable for use in many different environments, where it can selectively activate a group of chymotrypsin-like proteases and presumably also other proteins. The massive body of the exclusion domain blocks the active site of cathepsin C beyond the S2 binding site [66, 67 ]. An exposed ␤-hairpin, the first N-terminal residues of the exclusion domain and the carbohydrate ring attached to Asn 5 block undesired access, while Asp 1 with its carboxylic group side chain controls entry into the S2 binding pocket by docking with the N-terminal amino group of a substrate. Asp 1 simultaneously prevents the positively charged side chains of arginine and lysine residues from binding into the S2 binding pocket. An additional special feature of cathepsin C is the dependence of its activity on chloride ions, one of which is located at the bottom of the very long S2 binding pocket.
Conclusions
The papain-like cathepsins are rather non-specific enzymes with no clear substrate recognition site. The major substrate-binding determinants are mainchain atoms, which interact with the conserved structural features of the S2, S1 and S1Ј substrate-binding sites. The vast majority of low-molecular-mass inhibitors additionally utilize a covalent interaction with the reactive-site cysteine. This does not imply that specific inhibitors cannot be designed. It does, however, suggest that specificity is not an issue of a single binding site, but rather a sum of all interactions. This suggests that inhibitor constructs interacting with regions on both sides of the reactive site may be advantageous compared with those that bind only into one side. The specificity of exopeptidases is more a matter of exclusive interactions of free-chain termini than of side-chain recognition. The design of exopeptidase inhibitors therefore seems easier. Structural observations raise the question of whether the substrate-binding sites are indeed the only potential determinants for the design of specific inhibitors. The crystal structures of complexes with protein inhibitors [68, 69] have revealed that stefins and cystatins, rather non-selective inhibitors of papain-like proteases, interact with the non-specific features located at the bottom of the active-site cleft. However, thyropin, the inhibitory fragment of the p41 form of the MHC class II-associated invariant chain, forms contacts along the active-site cleft as well as with surface loops on the top of the L-domain.
